Hennion & Walsh Asset Management, Inc. Nektar Therapeutics Transaction History

Hennion & Walsh Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$0.51 - $1.05 $7,381 - $15,196	-14,473 Reduced 16.49%	73,313 $43,000
Q2 2023 Aug 09, 2023	BUY	$0.53 - $1.03 $489 - $951	924 Added 1.06%	87,786 $50,000
Q1 2023 Apr 20, 2023	SELL	$0.64 - $3.15 $1,306 - $6,432	-2,042 Reduced 2.3%	86,862 $61,000
Q4 2022 Jan 12, 2023	SELL	$2.03 - $4.28 $272,310 - $574,132	-134,143 Reduced 60.14%	88,904 $201,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $32,591 - $55,105	-10,721 Reduced 4.59%	223,047 $714,000

Q2 2022 Jul 19, 2022	SELL	$3.17 - $6.17 $302,861 - $589,481	-95,540 Reduced 29.01%	233,768 $888,000
Q1 2022 Apr 26, 2022	BUY	$4.16 - $13.72 $81,852 - $269,954	19,676 Added 6.35%	329,308 $1.78 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $270,966 - $460,618	25,020 Added 8.79%	309,632 $4.18 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $120,792 - $174,119	-9,242 Reduced 3.15%	284,612 $5.11 Million
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $481,607 - $594,721	29,153 Added 11.01%	293,854 $5.04 Million
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $4.38 Million - $6.74 Million	264,701 New	264,701 $5.29 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.